CN107698594A - 吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途 - Google Patents

吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途 Download PDF

Info

Publication number
CN107698594A
CN107698594A CN201710652268.7A CN201710652268A CN107698594A CN 107698594 A CN107698594 A CN 107698594A CN 201710652268 A CN201710652268 A CN 201710652268A CN 107698594 A CN107698594 A CN 107698594A
Authority
CN
China
Prior art keywords
preparation
compound
bases
substituted
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710652268.7A
Other languages
English (en)
Chinese (zh)
Inventor
梅德盛
刘爱风
汪奎
孙靖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Guokuang Pharmaceutical Technology Co ltd
Original Assignee
Hangzhou Anuo Biological Medicine Technology Co Ltd</en>
Suzhou State Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Anuo Biological Medicine Technology Co Ltd</en>, Suzhou State Pharmaceutical Technology Co Ltd filed Critical Hangzhou Anuo Biological Medicine Technology Co Ltd</en>
Publication of CN107698594A publication Critical patent/CN107698594A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201710652268.7A 2016-08-09 2017-08-02 吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途 Pending CN107698594A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016106472043 2016-08-09
CN201610647204 2016-08-09

Publications (1)

Publication Number Publication Date
CN107698594A true CN107698594A (zh) 2018-02-16

Family

ID=61161660

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710652268.7A Pending CN107698594A (zh) 2016-08-09 2017-08-02 吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途

Country Status (2)

Country Link
CN (1) CN107698594A (fr)
WO (1) WO2018028491A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108424414A (zh) * 2017-12-08 2018-08-21 苏州国匡医药科技有限公司 一类含杂环的吲哚胺2，3-双加氧酶调节化合物及其在药学中的用途
CN111116614A (zh) * 2018-11-01 2020-05-08 复旦大学 免疫调节因子与紫杉烷的共价链接物及其白蛋白纳米制剂及制备方法
CN111617078A (zh) * 2019-02-28 2020-09-04 四川科伦博泰生物医药股份有限公司 用于疾病治疗和/或预防的药物组合物、方法及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037026A1 (fr) * 2014-09-05 2016-03-10 Merck Patent Gmbh Composés diaza et triaza tricycliques à substitution cyclohexyl-éthyle utilisés comme antagonistes de l'indoleamine-2,3-dioxygénase (ido) pour le traitement du cancer
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
WO2016165613A1 (fr) * 2015-04-12 2016-10-20 Hangzhou Innogate Pharma Co., Ltd. Hétérocycles utiles comme inhibiteurs d'ido et de tdo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (fr) * 2011-04-15 2018-03-17

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037026A1 (fr) * 2014-09-05 2016-03-10 Merck Patent Gmbh Composés diaza et triaza tricycliques à substitution cyclohexyl-éthyle utilisés comme antagonistes de l'indoleamine-2,3-dioxygénase (ido) pour le traitement du cancer
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
WO2016165613A1 (fr) * 2015-04-12 2016-10-20 Hangzhou Innogate Pharma Co., Ltd. Hétérocycles utiles comme inhibiteurs d'ido et de tdo

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108424414A (zh) * 2017-12-08 2018-08-21 苏州国匡医药科技有限公司 一类含杂环的吲哚胺2，3-双加氧酶调节化合物及其在药学中的用途
CN111116614A (zh) * 2018-11-01 2020-05-08 复旦大学 免疫调节因子与紫杉烷的共价链接物及其白蛋白纳米制剂及制备方法
CN111116614B (zh) * 2018-11-01 2022-12-13 复旦大学 免疫调节因子与紫杉烷的共价链接物及其白蛋白纳米制剂及制备方法
CN111617078A (zh) * 2019-02-28 2020-09-04 四川科伦博泰生物医药股份有限公司 用于疾病治疗和/或预防的药物组合物、方法及其用途

Also Published As

Publication number Publication date
WO2018028491A1 (fr) 2018-02-15

Similar Documents

Publication Publication Date Title
CN105517999B (zh) Ido抑制剂
CN105473550B (zh) Ido抑制剂
ES2883285T3 (es) Antagonistas de tlr7/8 y sus usos
US11866432B2 (en) Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
RU2758686C2 (ru) Антагонисты tlr7/8 и их применение
CN105658643B (zh) Ido抑制剂
CN105324362B (zh) Ido抑制剂
CN104302649B (zh) 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
CN105503862B (zh) 流感病毒复制抑制剂
CA3041942C (fr) Compose amino-pyrazolopyrimidine utilise en tant qu&#39;inhibiteur du recepteur de la tyrosine kinase du facteur neurotrophique
ES2697607T3 (es) Compuestos sustituidos de piridinon-piridinilo
JP2015061877A (ja) Ｉｄｏ阻害剤
BR112020014151A2 (pt) Compostos de benzamida
TW201028386A (en) Novel bicyclic heterocyclic compound
MX2015002696A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de hepatitis b.
CN107021929A (zh) 一类新型ido抑制剂、制备方法、药物组合物及其用途
JP2018505166A (ja) Ｉｒａｋ阻害剤としてのピリダジノン大環状化合物及びその使用
JP7148500B2 (ja) 新規テトラヒドロナフチルウレア誘導体
CN107922353A (zh) Ido抑制剂
CA3090493A1 (fr) Analogues de benzothiophene substitues en tant qu&#39;agents de degradation selectifs du recepteur d&#39;ƒstrogenes
JP6126040B2 (ja) ニコサミド（Ｎｉｃｏｕｓａｍｉｄｅ）化合物の五つの晶型、その製法やその薬物組合と用途
CN106687453B (zh) 作为溴结构域抑制剂的四氢喹啉衍生物
CN107698594A (zh) 吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途
CN103502219A (zh) 作为治疗剂的新型小分子
CN106573901A (zh) 富马酸酯类似物及其在治疗自身免疫性疾病或炎性疾病中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 215125 Biological Park, Suzhou, Jiangsu, industrial park, A3-412

Applicant after: SUZHOU GUOKUANG PHARMACEUTICAL TECHNOLOGY Co.,Ltd.

Applicant after: Hangzhou Arnold Biomedical Technology Co.,Ltd.

Address before: 215125 Biological Park, Suzhou, Jiangsu, industrial park, A3-412

Applicant before: SUZHOU GUOKUANG PHARMACEUTICAL TECHNOLOGY Co.,Ltd.

Applicant before: HANGZHOU ANUO BIOLOGICAL MEDICINE TECHNOLOGY Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200826

Address after: A4-302, biomedical industrial park, 218 Xinghu street, Suzhou Industrial Park (Wuzhong District), 215100, Jiangsu Province

Applicant after: SUZHOU GUOKUANG PHARMACEUTICAL TECHNOLOGY Co.,Ltd.

Address before: 215125 Biological Park, Suzhou, Jiangsu, industrial park, A3-412

Applicant before: SUZHOU GUOKUANG PHARMACEUTICAL TECHNOLOGY Co.,Ltd.

Applicant before: Hangzhou Arnold Biomedical Technology Co.,Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180216